Close
Almac
Achema middle east

Elsevier integrates Reaxys with electronic laboratory notebook

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

UK Plans to Produce Cancer Treatment from Nuclear Waste

Bicycle Therapeutics has entered into a 15-year agreement with...
- Advertisement -

PerkinElmer has integrated its electronic laboratory notebook (ELN) with Elsevier’s Reaxys, a web-based workflow solution designed for chemistry researchers in drug discovery, chemicals and academic research.

PerkinElmer Informatics general manager Michael Stapleton said as chemists are turning to electronic laboratory notebooks to plan, execute and record their experiments, they also need ready access to complementary tools and data sources directly within the ELN interface.

“The interoperability of our ELN and Elsevier’s Reaxys provides researchers with access to extensive information on chemical compounds and related physical and pharmacological properties so that they can make better decisions,” Stapleton added.

”This integration also allows researchers to save valuable time by providing the ability to rapidly search and import external data while eliminating transcription errors.”

The new integrated solution enables access to reaction and substance data directly from Reaxys into the ELN for enhanced productivity and streamlined workflows.

The chemical searches in Reaxys can be initiated in an experimental section in the ELN based on existing or newly drawn compounds or reactions and results are made immediately available.

PerkinElmer provides discovery, collaboration and knowledge enterprise solutions, desktop software, scientific databases and consulting services to the pharmaceutical, biotechnology, and chemical industries.

Latest stories

Related stories

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

UK Plans to Produce Cancer Treatment from Nuclear Waste

Bicycle Therapeutics has entered into a 15-year agreement with...

Regeneron Looks to Infusing More Funds into Gene Editing

Regeneron Pharmaceuticals is going ahead and investing more funds...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »